99 related articles for article (PubMed ID: 2004569)
1. [Serum ribonuclease in patients with malignant tumor of the ovary].
Liu SS; Cai GR
Zhonghua Fu Chan Ke Za Zhi; 1991 Jan; 26(1):17-20, 61. PubMed ID: 2004569
[TBL] [Abstract][Full Text] [Related]
2. [Serum lipid-associated sialic acid (LSA) in diagnosing and monitoring ovarian cancer].
Yue K; Bian M; Zhu D; Liu W; Siu S
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1995 Apr; 17(2):128-32. PubMed ID: 7656393
[TBL] [Abstract][Full Text] [Related]
3. [Serum ribonuclease activity in gynecologic neoplasms. The behavior of serum ribonuclease in ovarian cancer under cytostatic therapy].
Schleich HG; Wiest W
Fortschr Med; 1980 Sep; 98(36):1384-6. PubMed ID: 7461546
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of combined use of macrophage colony-stimulating factor and squamous cell carcinoma antigen as a selective diagnostic marker for squamous cell carcinoma arising in mature cystic teratoma of the ovary.
Suzuki M; Tamura N; Kobayashi H; Ohwada M; Terao T; Sato I
Gynecol Oncol; 2000 Jun; 77(3):405-9. PubMed ID: 10831350
[TBL] [Abstract][Full Text] [Related]
5. [Detection of serum sialic acid in three kinds of malignant tumor and its clinical significance].
Liang XH; Liang XM; Yi B
Hunan Yi Ke Da Xue Xue Bao; 2003 Feb; 28(1):65-6. PubMed ID: 12934403
[TBL] [Abstract][Full Text] [Related]
6. [The diagnostic value of the assay of lactate dehydrogenese combined with other tumor markers in ovarian cancer].
Tang BJ; Li L; Xu J
Zhonghua Fu Chan Ke Za Zhi; 1994 Jun; 29(6):336-9, 381. PubMed ID: 8001406
[TBL] [Abstract][Full Text] [Related]
7. Relationship of serum levels of tumor markers with tissue expression of gene products in ovarian carcinoma.
Sorak M; Arsenijević S; Lukić G; Arsenijević N; Ristić P; Pavlović S; Popović S; Baskić D
J BUON; 2007; 12(1):99-104. PubMed ID: 17436409
[TBL] [Abstract][Full Text] [Related]
8. [Investigation of serum immunosuppresive acidic protein levels in gynecological tumor].
Zhang W; Wang P; Zhao Y
Zhonghua Yi Xue Za Zhi; 1999 Mar; 79(3):194-6. PubMed ID: 11601039
[TBL] [Abstract][Full Text] [Related]
9. Dysgerminoma and serum lactic dehydrogenase levels.
Awais GM
Obstet Gynecol; 1983 Jan; 61(1):99-101. PubMed ID: 6823354
[TBL] [Abstract][Full Text] [Related]
10. Plasma lipid-associated sialic acid and serum CA 125 as indicators of disease status with advanced ovarian cancer.
Vardi JR; Tadros GH; Foemmel R; Shebes M
Obstet Gynecol; 1989 Sep; 74(3 Pt 1):379-83. PubMed ID: 2761915
[TBL] [Abstract][Full Text] [Related]
11. [Application of monoclonal antibody OC 125 in gynecological oncology].
Wu AR; Wang EY; Wang XX; Jia XH; Li L
Zhonghua Zhong Liu Za Zhi; 1988 Mar; 10(2):132-6. PubMed ID: 3208653
[TBL] [Abstract][Full Text] [Related]
12. Macrophage colony-stimulating factor as a marker for malignant germ cell tumors of the ovary.
Suzuki M; Kobayashi H; Ohwada M; Terao T; Sato I
Gynecol Oncol; 1998 Jan; 68(1):35-7. PubMed ID: 9454657
[TBL] [Abstract][Full Text] [Related]
13. [Sialic acid in the serum--an indicator for malignant growth?].
Schulze G
Arch Geschwulstforsch; 1990; 60(1):19-24. PubMed ID: 2310297
[TBL] [Abstract][Full Text] [Related]
14. [Tumor markers in the monitoring of ovarian cancer].
Xu SX
Zhonghua Fu Chan Ke Za Zhi; 1990 Nov; 25(6):345-7, 383. PubMed ID: 2282861
[TBL] [Abstract][Full Text] [Related]
15. [Preclinical and clinical studies on a tumor marker, galactosyltransferase associated with tumor (GAT), in ovarian cancer (second report)--clinical significance of GAT and comparison with other tumor markers].
Nozawa S; Udagawa Y; Ito K; Susumu N; Sasaki H; Aoki D
Gan To Kagaku Ryoho; 1993 Feb; 20(2):279-85. PubMed ID: 8434967
[TBL] [Abstract][Full Text] [Related]
16. [Study on serum vascular endothelial growth factor level in ovarian malignant tumors].
Li L; Wang LM; Zhang W; Zhang JQ; Song HL; Yao DS; Tang Y; Chen XQ; Yang ZH
Zhonghua Fu Chan Ke Za Zhi; 2003 Feb; 38(2):72-6. PubMed ID: 12783691
[TBL] [Abstract][Full Text] [Related]
17. [Changes of plasma ribonuclease activities according to the method of treatment in gynecologic cancer patients (author's transl)].
Sugawara S
Nihon Sanka Fujinka Gakkai Zasshi; 1981 Oct; 33(10):1749-56. PubMed ID: 7310199
[TBL] [Abstract][Full Text] [Related]
18. [Clinical significance of vascular endothelial growth factor in sera of patients with gynaecological malignant tumors].
Peng XP; Li JD; Li MD; Ye XM; Yan WC
Ai Zheng; 2002 Feb; 21(2):181-5. PubMed ID: 12479072
[TBL] [Abstract][Full Text] [Related]
19. A comparative study of serum alpha-beta A immunoreactive inhibin and tumor-associated antigens CA125 and CEA in ovarian cancer.
Phocas I; Sarandakou A; Sikiotis K; Rizos D; Kalambokis D; Zourlas PA
Anticancer Res; 1996; 16(6B):3827-31. PubMed ID: 9042265
[TBL] [Abstract][Full Text] [Related]
20. Accuracy of tissue polypeptide specific antigen (TPS) in the diagnosis of ovarian malignancy.
Padungsutt P; Thirapagawong C; Senapad S; Suphanit I
Anticancer Res; 2000; 20(2B):1291-5. PubMed ID: 10810437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
